• Profile
Close

Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: A randomized, phase 2 study

Rheumatology Sep 12, 2018

Russell SJ, et al. – This phase 2, double-blind, randomized, parallel-group trial of 33 patients with knee osteoarthritis and comorbid type 2 diabetes mellitus (T2DM) compared blood glucose levels after intra-articular injection of triamcinolone acetonide extended-release (TA-ER)—an extended-release, microsphere-based triamcinolone acetonide formulation—vs standard triamcinolone acetonide crystalline suspension. Between groups, non-glycemic adverse events were mild in severity and comparable. In patients with knee osteoarthritis and T2DM, findings showed that TA-ER may enable intra-articular corticosteroid treatment with minimal blood glucose disruption.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay